IPCA Laborities Limited
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments.
API Buisness
Ipca produces over 80 APIs, nearly 79% of the APIs and Intermediates business is from exports making them one of India’s top exporters of APIs, serving over 100 countries around the globe. The core strategic focus has been on backward integration, resulting in superior supply chain reliability and cost competitiveness .
Manufacturing Facilties
The Company has 18 manufacturing units in India manufacturing APIs and formulations for the world market and Leading brands in Pain, Rheumatology, Antimalarials, and Haircare therapy in India.
Shareholding Pattern
- Promoters
- Public
Financial Summary
| Particulars | March 2024 | March 2023 | March 2022 |
| Sales | 7,705 | 6,204 | 5,797 |
| Sales Growth % | 24.19% | 7.03% | 7.45% |
| Operating Profit | 1,321 | 932 | 1,325 |
| OPM % | 17% | 15% | 23% |
| Profit before tax | 843 | 745 | 1,136 |
| YOY Growth | – | 7% | 7% |
| EPS in Rs | 21.57 | 18.58 | 34.85 |
Synopsis of Financials
- Sales has increased due to increase in sale of products.
- Moreover, Revnue has increased from sale of services.
- Majorly Profit of the company sale of products.
Final Outlook
Ipca Laboratories shares continued to trade in negative territory.During market hours on Wednesday, May 29, Ipca Labs reported a 22.12 per cent year-on-year (YoY) fall in Q4FY24 consolidated net profit to ₹59.59 crore compared to a profit of ₹76.52 crore in the same period last year.However, the company’s revenue rose 34.5 per cent YoY to ₹2,033.01 crore compared with ₹1,511.63 crore in the same quarter last year.Manufacturing sector growth expected to be slightly slower in the coming year.Focus on cost efficiency and consolidation continuing in the market.Positive outlook for Europe market performance. But Fundamentally the revenue of ipca lab is going downwards from last 3 years.so recommendation is to hold it as the future accept is good of the company.
Ipca-Laborities-Limited-